Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79893.900.0668%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Vir Biotechnology Inc

VIRNASDAQ
Trade with Public
Trade with Public
$11.38
-0.065-0.57%
At close: Sep 4, 5:00 PM EST
$11.40
0.0150.13%
After Hours: Sep 4, 6:39 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Vir Biotechnology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Vir Biotechnology (VIR).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

9Buy
1Hold
Consensus RatingBuy# Analysts10Avg. Consensus PT$28Upside to Avg. PT+145.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jun 11, 2026Morgan StanleyMichelle GilsonPT RaiseOverweight$23→$27
Jun 3, 2026Leerink PartnersRoanna RuizPT RaiseOutperform$20→$21
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27

Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $23 to $27.
Benzinga Newsdesk

PRO
Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21

Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $20 to $21.
Benzinga Newsdesk

Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday

Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/downgrades, see analyst ratings page.
Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to $20.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $30

Barclays analyst Etzer Darout maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $26 to $30.
Benzinga Newsdesk

These Analysts Boost Their Forecasts On Vir Biotechnology

Avi Kapoor

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved